Researchers from UCSD and the Gladstone Institute of Cardiovascular Disease have developed a system for genomic-based drug screening that combines mRNA profiling and an automated, high throughput sequencing platform. Startup 255Xpress has licensed the technology and is adapting it for a variety of drug screening assays.